Early test: can a common acid boost cancer treatment?
NCT ID NCT07325123
Summary
This early-stage study aims to see if adding an oral malic acid supplement to standard immunotherapy is safe and might help control solid tumors like lung or colorectal cancer. It will involve about 30 adults already receiving immunotherapy. Researchers will check for side effects, look for early signs of tumor response, and measure changes in immune and nutritional health.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.